J. Juco

发表

Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothe

Carsten Denkert, Fred Hirsch, Benjamin Solomon, 2017, Advances in anatomic pathology.

Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.

J. Lunceford, E. Plimack, R. Berger, 2015 .

The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation

J. Taube, I. Wistuba, Emanuel Schenck, 2020, Journal for immunotherapy of cancer.

Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer

Andrew H. Beck, Jacqueline A. Hall, Sarah N. Dudgeon, 2020, npj Breast Cancer.

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

J. Lunceford, E. Plimack, R. Berger, 2017, The Lancet. Oncology.

Ventilator-induced coagulopathy in experimental Streptococcus pneumoniae pneumonia

Arthur S Slutsky, J. Juco, M. Levi, 2008, European Respiratory Journal.

Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry.

Shiyong Li, J. Juco, K. Mann, 2003, American journal of clinical pathology.

Anaplastic Large Cell Lymphomas Presented as Bone Lesions: A Clinicopathologic Study of Six Cases and Review of the Literature

J. Juco, L. Medeiros, R. Lai, 2000, Modern Pathology.

Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients

J. Juco, S. Khambata-Ford, P. Hofman, 2018, Cancer cytopathology.

Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors with the immunohistochemistry assay PD-L1 IHC 22C3 pharmDx.

J. Juco, K. Emancipator, D. Stanforth, 2017 .

Rectal gastrointestinal stromal tumor mimicking a primary prostatic lesion.

J. Srigley, B. Dickson, A. Pollett, 2008, The Canadian journal of urology.

Inhibition of Poly(Adenosine Diphosphate–Ribose) Polymerase Attenuates Ventilator-induced Lung Injury

Arthur S Slutsky, J. Juco, Haibo Zhang, 2008, Anesthesiology.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

J. Lunceford, T. Mcclanahan, J. Juco, 2017, Clinical Cancer Research.

The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice

A. Gown, T. Nielsen, E. Thompson, 2020, The Journal of pathology.

Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.

J. Lunceford, J. Juco, K. Emancipator, 2018, Archives of pathology & laboratory medicine.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.

J. Lunceford, Y. Bang, J. Juco, 2016, The Lancet. Oncology.

Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

C. Copie-Bergman, J. Juco, S. Khambata-Ford, 2017, PloS one.

Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

C. Copie-Bergman, J. Juco, S. Khambata-Ford, 2017, PloS one.

Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemias.

J. Juco, R. Lai, R. Lai, 2000, American journal of clinical pathology.

Parathyroid Chief Cell Adenoma Associated with Massive Chronic Parathyroiditis in a Woman with Hyperparathyroidism

J. Juco, K. Kovacs, Jennifer Anderson, 2007, Endocrine pathology.

Primary Pituitary Lymphoma: A Histological, Immunohistochemical, and Ultrastructural Study with Literature Review

B. Scheithauer, J. Juco, K. Kovacs, 2009, Endocrine pathology.

Flow cytometry in the differential diagnosis of lymphocyte-rich thymoma from precursor T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma.

Shiyong Li, J. Juco, K. Mann, 2004, American journal of clinical pathology.

Hemangiopericytoma of the sella mimicking pituitary adenoma: case report and review of the literature.

J. Juco, K. Kovacs, H. Smyth, 2007, Clinical neuropathology.

Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study.

J. Lunceford, E. Plimack, R. Berger, 2017, The Lancet. Oncology.

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

J. Lunceford, T. Mcclanahan, J. Juco, 2017, Clinical Cancer Research.

Inhibition of Poly(Adenosine Diphosphate–Ribose) Polymerase Attenuates Ventilator-induced Lung Injury

Arthur S Slutsky, J. Juco, Haibo Zhang, 2008, Anesthesiology.

Investigation of PD-L1 expression and response to pembrolizumab (pembro) in gastric cancer (GC) and cervical cancer (CC) using combined positive score (CPS) and tumor proportion score (TPS).

J. Lunceford, M. Marton, J. Juco, 2018 .

Analysis of efficacy outcomes based on programmed death ligand 1 (PD-L1) scoring techniques in patients with head and neck squamous cell carcinoma (HNSCC) from KEYNOTE-040

K. Harrington, J. Juco, K. Emancipator, 2019, Annals of Oncology.